Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Marcia L. Moss"'
Autor:
Marcia L. Moss, Dmitry Minond
Publikováno v:
Mediators of Inflammation, Vol 2017 (2017)
Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroa
Externí odkaz:
https://doaj.org/article/dfcab54e8f904d6a9e15533358ba6254
Development of flow cytometry assays for measuring cell-membrane enzyme activity on individual cells
Autor:
Nikola L. Vujanovic, Laura P. Stabile, Toshie Yoneyama, Michael C. Gorry, Marcia L. Moss, Lazar Vujanovic, Miles A. Miller, James G. Herman, Michelle A. Garlin
Publikováno v:
Journal of Cancer
Background: Cell-membrane expressing enzymes such as ADAM (a disintegrin and metalloproteinase) superfamily members are thought to be key catalysts of vital cellular functions. To directly measure these enzymes and determine their association with pa
Autor:
Linda G. Griffith, Michael C. Gorry, Miles A. Miller, Nikola L. Vujanovic, Autumn Gaither-Davis, Marcia L. Moss, Lazar Vujanovic, Yan Lin, James G. Herman, Andrea Sobo-Vujanovic, Douglas A. Lauffenburger, Laura P. Stabile, Toshie Yoneyama
Publikováno v:
Journal of Cancer
Background: Increases in expression of ADAM10 and ADAM17 genes and proteins are inconsistently found in cancer lesions, and are not validated as clinically useful biomarkers. The enzyme-specific proteolytic activities, which are solely mediated by th
Autor:
Douglas A. Lauffenburger, Toshie Yoneyama, James G. Herman, Autumn Gaither-Davis, Laura P. Stabile, Marcia L. Moss, Linda G. Griffith, Michael C. Gorry, Yan Lin, Miles A. Miller, Nikola L. Vujanovic
Publikováno v:
Journal of Cancer
Increases in expression of ADAM10 and ADAM17 genes and proteins have been evaluated, but not validated as cancer biomarkers. Specific enzyme activities better reflect enzyme cellular functions, and might be better biomarkers than enzyme genes or prot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d907f27ac7ad7ca40dc0345beb81a7
http://hdl.handle.net/1721.1/117613
http://hdl.handle.net/1721.1/117613
Autor:
Dmitry Minond, Marcia L Moss
Publikováno v:
Mediators of Inflammation, Vol 2017 (2017)
Mediators of Inflammation
Mediators of Inflammation
Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroa
Publikováno v:
Journal of Neurochemistry. 128:267-279
EphrinA/EphA-dependent axon repulsion is crucial for synaptic targeting in developing neurons but downstream molecular mechanisms remain obscure. Here, it is shown that ephrinA5/EphA3 triggers proteolysis of the neural cell adhesion molecule (NCAM) b
Publikováno v:
Analytical biochemistry. 514
A disintegrin and metalloproteinase 15 (ADAM15), also known as metargidin, plays important roles in regulating inflammation, wound healing, neovascularization, and is an attractive drug target. Fluorescence resonance energy transfer (FRET)-based pept
Autor:
Fred H. Rasmussen, Nikola L. Vujanovic, Marcia L. Moss, Hinrich P. Hansen, Dmitriy Minond, Toshie Yoneyama
Publikováno v:
Analytical biochemistry. 507
A fluorescent resonance energy transfer substrate with improved sensitivity for ADAM17, −10, and −9 (where ADAM represents a disintegrin and metalloproteinase) has been designed. The new substrate, Dabcyl-Pro-Arg-Ala-Ala-Ala-Homophe-Thr-Ser-Pro-L
Autor:
Marcia L. Moss
Publikováno v:
Molecular Enzymology and Drug Targets.
The most popular drugs for treating HER2 positive breast cancer are Trastuzumab or lapatinib. Clinical trials in recent years have begun where the two drugs are now being used in combination. Some of the trial results appear to be promising and the c
Publikováno v:
Clinical Biochemistry. 44:1434-1439
Objectives MMP-2, MMP-9, their complexes and ADAM12 are detected in the urine of breast cancer patients and predict disease status. We assessed the use of FRET-based substrates in an assay to distinguish breast cancer patients from controls. Design a